Objective-Atherosclerosis, the cause of 50% of deaths in westernized societies, is widely regarded as a chronic vascular inflammatory disease. Vascular smooth muscle cell (VSMC) inflammatory activation in response to local proinflammatory stimuli contributes to disease progression and is a pervasive feature in developing atherosclerotic plaques. Therefore, it is of considerable therapeutic importance to identify mechanisms that regulate the VSMC inflammatory response. Approach and Results-We report that myocardin, a powerful myogenic transcriptional coactivator, negatively regulates VSMC inflammatory activation and vascular disease. Myocardin levels are reduced during atherosclerosis, in association with phenotypic switching of smooth muscle cells. Myocardin deficiency accelerates atherogenesis in hypercholesterolemic apolipoprotein E −/− mice. Conversely, increased myocardin expression potently abrogates the induction of an array of inflammatory cytokines, chemokines, and adhesion molecules in VSMCs. Expression of myocardin in VSMCs reduces lipid uptake, macrophage interaction, chemotaxis, and macrophage-endothelial tethering in vitro, and attenuates monocyte accumulation within developing lesions in vivo. These results demonstrate that endogenous levels of myocardin are a critical regulator of vessel inflammation. Conclusions-We propose myocardin as a guardian of the contractile, noninflammatory VSMC phenotype, with loss of myocardin representing a critical permissive step in the process of phenotypic transition and inflammatory activation, at the onset of vascular disease.
C ardiovascular diseases are the cause of substantial mortality and morbidity across the Western and, increasingly, the developing worlds. 1, 2 Chronic inflammation is a pathological process that represents a common, critical hallmark in the development of multiple occlusive vascular diseases, including transplant vasculopathy, interventional restenosis, and atherosclerosis. 3, 4 Vascular smooth muscle cells (VSMCs) undergo a unique, coordinated morphological and functional transition between contractile and synthetic states in injury and disease. 5 Inflammatory activation of medial VSMCs refers to the attainment of a phenotypic state, in which cells secrete a diverse range of proinflammatory mediators, such as cytokines, chemokines, and adhesion molecules, in response to a variety of signals in the surrounding milieu. VSMC inflammatory activation contributes to vessel pathophysiology, vascular disease progression and ultimately, adverse clinical outcome. 6, 7 Therefore, it is of considerable therapeutic importance to identify mechanisms that regulate the VSMC inflammatory response.
Myocardin (Myocd) is a potent myogenic coactivator, expressed specifically in contractile smooth and cardiac muscle tissues in adulthood, and respective progenitor cells during embryonic development. [8] [9] [10] [11] Myocardin associates strongly with serum response factor and stabilizes binding at the degenerate CC(A/T-rich) 6 GG (CArG) cis-elements of all known CArG-dependent SMC marker genes. 5, 12 Myocardin homozygous-null (Myocd −/− ) mice exhibit impaired SMC development and die at embryonic day 10.5, 13 although Myocd −/− embryonic stem cells retain some capacity to differentiate into SMC lineages in vitro and in vivo. 14, 15 However, myocardin-deficient VSMCs show reduced expression of contractile apparatus and exhibit ultrastructural features associated with the synthetic phenotype. 16 A growing number of studies report a correlation between vascular injury or disease progression, and reduced myocardin expression [17] [18] [19] [20] [21] or alternative splicing of myocardin pre-mRNA. 22 Furthermore, Lovren et al 23 observed that attenuated lesion development after miR-145 administration to VSMCs in hypercholesterolemic apolipoprotein E (ApoE) −/− mice coincided with increased myocardin levels. However, despite previous in vitro evidence that myocardin negatively regulates VSMC proliferation, 9, 11, 24 this association is consistently regarded as secondary to disease progression, and myocardin is referred to purely as a marker of SMC contractile gene expression. Recently, we set out to address this shortcoming, and identified myocardin as a critical regulator of the vessel injury response in vivo. 25 Re-expression of myocardin suppressed neointima formation in murine carotid arteries, whereas myocardin-heterozygous-null (Myocd +/− ) mice displayed augmented neointima formation with increased VSMC migration and proliferation. Using both loss and gain-of-function models, in vitro and in vivo, we now demonstrate that myocardin is a central negative regulator of VSMC inflammatory activation and associated vascular disease.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Myocardin Expression Is Reduced in VSMCs at the Onset of Vascular Disease
Studies in mice and swine have shown that expression of myocardin in the vascular wall is decreased after injury and in atherosclerosis, associated with reduced SMC marker gene expression. [17] [18] [19] [20] To examine the reproducibility and temporal dynamics of these observations in an established model of atherosclerosis, we examined myocardin expression after placement of a nonconstrictive collar around the common carotid arteries of high-fat diet-fed LDLR −/− mice. 26, 27 In this model, significant neointimal lesions develop by 6 weeks after collar placement. A marked downregulation of myocardin RNA expression was confirmed 2 weeks after surgery (P<0.01; Figure 1A ), accompanied by concomitant fall in SMC marker gene expression ( Figure 1B ). These data demonstrate that downregulation of myocardin is an early and consistent feature of vascular disease, as in vascular injury. 25 Subsequent analysis of healthy aortic and diseased carotid human artery samples confirmed that myocardin expression is similarly reduced in diseased human vessels compared with healthy controls (P<0.05; Figure 1C ). Differential myocardin expression is maintained in their respective human artery VSMC cultures ( Figure 1D ), indicating that the change is intrinsic to VSMCs, and not attributable to differential VSMC numbers relative to other cell types within healthy and diseased vessel walls.
Myocardin Deficiency Is Causal for Accelerated Vascular Disease
Myocd +/− mice have reduced aortic myocardin expression, but similar levels of myocardin-like transcription factors MKL1 and MKL2, compared with wild-type (WT) littermates ( Figure  IA in the online-only Data Supplement). 25 These mice show a novel phenotype of augmented neointima formation after vascular injury, with increased VSMC migration and proliferation. 25 To determine whether reduced myocardin expression in VSMCs represents a critical permissive step in early vascular disease progression, Myocd +/− mice were crossed onto an ApoE −/− background. 28 Mice were then administered highfat diet for 8 weeks, before analysis of atherosclerotic lesion development in the aortic root. A relatively short period of fat-feeding was selected to visualize early stages of vascular disease, whereby accelerated progression could present most clearly. ApoE −/− .Myocd +/− mice exhibited a significant, close to 50% mean increase in plaque area, compared with ApoE −/− . Myocd +/+ (WT) littermate controls (P=0.05; Figure 1E -1G). Total medial area was unchanged between groups. A complete set of aortic root cross-section images analyzed in this study is provided in Figure IIA in the online-only Data Supplement. A second independent study further substantiated these findings, showing a 25% mean increase in oil red O staining of lipid-rich regions in the aortic root of ApoE −/− . Myocd +/− mice compared with ApoE −/− .Myocd +/+ controls (P=0.04; Figure 1G -1H). Data from these loss-of-function studies provide the first compelling evidence that endogenous levels of myocardin negatively regulate the progress of atherosclerosis in vivo.
Myocardin-Deficient SMCs Exhibit Increased Potential for Inflammatory Activation
VSMC inflammatory activation contributes to the propagation of inflammation in the developing lesion, and to the progression of vascular disease. We hypothesized that myocardin may reduce vascular disease through suppression of VSMC phenotypic transition and inflammatory activation. It was reasoned that reduced VSMC inflammatory activation within a developing lesion would manifest in reduced inflammatory mediator production and reduced leukocyte infiltration. Indeed, increased numbers of LAMP2 (MAC3)-positive macrophage-like cells were observed in lesions of Myocd +/− mice compared with WT littermate controls (P<0.01; Figure 2A and 2B). IgG negative controls confirmed the specificity of LAMP2 immunostaining in the aortic root, whereas immunostaining against an alternative macrophage cell surface marker, CD68, recapitulated the Lamp2 staining results ( origin, we do not exclude the possibility that a proportion are VSMCs that have downregulated smooth muscle marker gene expression, upregulated macrophage markers, and assumed macrophage-like morphology. 29, 30 Consistent with increased leukocyte accumulation, we found significantly greater levels of circulating chemokine monocyte chemotactic protein-1 (CCL2) in Myocd +/− animals compared with WT littermates 4 weeks after initiation of the high-fat diet ( Figure 2C ). Immunostaining revealed similarly increased levels of CCL2 in the aortic lesions of Myocd +/− mice, compared with WT littermate controls ( Figure V in the onlineonly Data Supplement). Analysis of aortic root tissue harvested after 1 week of high-fat diet revealed earlier differences in inflammatory gene expression between Myocd +/− and WT mice ( Figure 2D ). Levels of the atherogenic cytokine interleukin (Il)-6 were significantly increased in aortic roots of Myocd +/− mice (P<0.05). 31 We also found increased expression of proinflammatory CCAAT/enhancer-binding protein transcription factors Cebpb and Cebpd in Myocd +/− aorta. No significant change in Ccl2 expression was observed, possibly reflecting specific temporal regulation of inflammatory gene expression, or clouding of differential signal from VSMCs by other cell types present in whole aortic root tissue.
To test whether increased inflammatory activation and leukocyte infiltration may indeed be driven specifically by myocardin-deficient VSMCs, medial aortic VSMCs were cultured from Myocd +/− mice and WT littermate controls. These cells were then exposed to varying concentrations of the proinflammatory cytokine IL-1β, which has been shown to elicit an inflammatory phenotypic state in VSMCs. 32 IL-1β-induced IL-6 release is an established indicator of VSMC inflammatory activation. 33 IL-1β induced a marked upregulation of Il-6 and Ccl2 mRNA, and levels were consistently and significantly higher in VSMCs derived from Myocd +/− mice ( Figure 2E and 2F). Furthermore, the mRNA expression of Cebpb and Cebpd was similarly increased in myocardin-deficient VSMCs ( Figure 2G and 2H).
Il-6 and CCL2 strongly recruit macrophages and monocytes to developing lesions, regulate the local expression of adhesion molecules, cytokines and the procoagulant tissue factor, and propagate inflammation in the nascent lesion. 7, 34, 35 CEBPB and CEBPD bind at the promoters of multiple inflammatory response genes, including Il-6 and Ccl2, and synergistically upregulate and sustain gene expression after inflammatory stimulation. [36] [37] [38] Upregulation of Il-6, Ccl2, Myocardin antagonises interleukin-1β-induced inflammatory pathways in vascular smooth muscle cells (VSMCs). A, Expression of inflammatory marker mRNA in human coronary artery smooth muscle cell (HCASMC) transfected with scrambled control siRNA or siRNA against myocardin (siMYOCD) for 24 hours, before treatment with 20 ng/mL interleukin-1β (IL-1β). Release of interleukin-6 (IL-6; B) and monocyte chemotactic protein-1 (CCL2; C) from HCASMCs transfected with scrambled control siRNA against myocardin (siMYOCD), CEBPB (siCEBPB), and CEBPD (siCEBPD), as indicated, for 24 hours, before treatment with 20 ng/mL interleukin-1β (IL-1β). IL-6 and CCL-2 release into surrounding media was quantified by ELISA. Data are presented as mean±SEM, n=3 independent experiments in biological triplicate. **P<0.01 and ***P<0.001 compared with scrambled siRNA-only control; #P<0.05 compared with siMYOCDonly treated cells. Rat aortic VSMCs were then transduced with adenoviral vectors (Ad) expressing dominant-negative myocardin (Ad. Myocd-DN) control, or myocardin (Ad.Myocd). D, mRNA expression of inflammatory and anti-inflammatory genes determined by realtime quantitative polymerase chain reaction (PCR) and presented in a heat map format, for VSMCs treated with Ad.Myocd-DN control or Ad.Myocd and stimulated for 4 hours with 20 ng/mL IL-1β. Red (high) and blue (low) depict differential gene expression relative to mean expression across all treatments. Source data are available for this figure ( Figure IA and Cebp factors in myocardin-deficient VSMC is, therefore, highly suggestive of fundamental transition toward a proinflammatory state. Enhanced VSMC inflammatory activation in myocardin-deficient VSMCs, thereby provides an endogenous mechanism by which accelerated vascular disease may proceed.
Myocardin Deficiency Amplifies Inflammatory Responses in Human VSMC
To test the relevance of myocardin deficiency in human disease, human coronary artery SMC (HCASMC) were grown and transfected with myocardin-specific small interfering RNA (siRNA). A reduction of roughly 50% myocardin expression was observed compared with controls ( Figure VI in the online-only Data Supplement). Consistent with observations in mouse VSMCs, reduced myocardin expression in HCASMC caused marked increases in IL-1β-induced IL6 and CCL2 production (P<0.001), both in terms of mRNA expression and protein secretion, as determined by enzymelinked immunosorbence assay ( Figure 3A -3C). Consistent with data from the Myocd +/− aortas, CEBPB and CEBPD expression were also increased in myocardin-deficient HCASMC (P<0.001 and P<0.01, respectively). Importantly, inhibition of CEBPB and CEBPD expression in the presence of myocardin deficiency was able to partially reverse the increase in inflammatory IL-6 and CCL2 marker production ( Figure 3B and 3C ). This finding is in line with our previous observation that siRNA-mediated inhibition of CebpB and CebpD can suppress IL-1β-induced expression of inflammatory mediators, such as Il-6 in rat aortic VSMC (data not shown). These data are thus consistent with our previous findings and support the relevance of myocardin in regulating vascular inflammation in human disease, regulation that may occur at least, in part, through the inhibition of intermediate inflammatory pathway mediators, such as CEBPB and CEBPD.
Myocardin Expression Suppresses Inflammatory Activation in Cultured VSMC
We next set out to test whether, conversely, augmented myocardin expression in VSMCs protects against the transition toward the inflammatory phenotype. Rat aortic VSMC, which grow reproducibly in culture and express low levels of endogenous myocardin, were treated with adenoviral expression constructs encoding myocardin (Ad.Myocd), or β-galactosidase (Ad.LacZ) and Myocd-DN (Ad.Myocd-DN) negative expression controls. Myocd-DN encodes a truncated form of myocardin that lacks the C-terminal transcription activating domain. 8 Efficient expression of relevant constructs was confirmed by Western Blotting (Figure IC and ID in the online-only Data Supplement). Myocardin and contractile SMC marker gene expression was significantly upregulated after Ad.Myocd administration ( Figure  VII in the online-only Data Supplement). Ad.Myocd-DN exerted no discernible dominant-negative effect, 39 probably because of low endogenous levels of myocardin in cultured rat VSMC. 9 Because of closer molecular similarity to Ad.Myocd, Ad.Myocd-DN was, therefore, used as the optimal negative expression control for in vitro studies. Complete data sets containing no-virus and Ad.LacZ controls are shown in Figure VIII in the online-only Data Supplement.
The inhibition of lipopolysaccharide-induced tumor necrosis factor-α and IL-6 production in aortic VSMC by myocardin has been reported previously. 24 Given the complexity of the atherogenic inflammatory process, 7 we elected to expand on this finding to investigate the effect of myocardin on the IL-1β-stimulated expression of a selection of cytokines, chemokines, and adhesion molecules with documented roles in atherosclerosis. Real-time reverse transcription polymerase chain reaction expression data are presented in heat-map format for ease of visualization ( Figure 3D ) and in full as bar charts ( Figure VIII in the online-only Data Supplement). Expression of myocardin was found to strongly and reproducibly suppress the IL-1β-induced expression of a diverse range of proinflammatory factors, including Il-6, Ccl-2, Nos2, Cxcl2, Cx3cl1, Vcam1 and Csf1. Notably, suppression was not universal, with Icam-1 apparently unaffected, and Csf-3 significantly upregulated in the presence of myocardin. Myocardin also significantly reduced the expression of inflammationmediating IL-1 receptors I1r1 and Il1r2, the IL-6 receptor Il6r, the tumour necrosis factor receptor Tnfrsf1a and the oxidized low-density lipoprotein scavenger receptor Olr1, which is consistent with reduced potential for inflammatory activation. Furthermore, myocardin expression upregulated the putative anti-inflammatory cytokine Il-19, 40,41 and 2 members of the immunosuppressive suppressor of cytokine signaling (SOCS) family, Socs2 and Socs6. 42 Given our previous finding of increased inflammatory activation in HCASMC treated with MYOCD siRNA, we tested whether Ad.Myocd-DN might exhibit a dominant effect in this setting of potentially higher endogenous myocardin. However, no significant effect was observed, although there was a trend toward decreased expression of the smooth muscle marker gene Myh11 in the presence of Ad.Myocd-DN ( Figure Production of inflammatory factors in VSMCs is controlled pretranslationally, typically at the level of transcription. 7, 43 Analysis of cell supernatants by ELISA confirmed a marked induction of IL-6 and CCL2 protein secretion from IL-1β-stimulated rat VSMCs, which was robustly abrogated after administration of Ad.Myocd (P<0.001; Figure 3E and 3F). IL-6 release in response to stimulation by tumor necrosis factor-α and lipopolysaccharide was also suppressed by myocardin ( Figure XI Figure 3G and 3H). Reduced abundance of both active isoforms of CEBPB, LAP* and LAP, 44 and CEBPD, were observed by Western blotting ( Figure 3I ). Furthermore, analysis of the Il6 promoter by chromatin immunoprecipitation revealed a marked increase in CEBPB protein binding after IL-1β stimulation, which was abrogated in the presence of Myocd expression ( Figure 3J ). However, no significant changes in binding of CEBPB to the Ccl2 promoter were detected. Binding of CEBPD was also not detected, despite analysis of multiple putative-binding regions at the Ccl2 promoter ( Figure XII in the online-only Data Supplement), although this may be attributable to a paucity of chromatin immunoprecipitation-grade antibodies available to target CEBPD.
Taken together, these data demonstrate that myocardin expression can actively and specifically suppress multiple facets of inflammatory activation in cultured VSMC, including the intracellular inflammatory pathway mediators CEBPB and CEBPD and furthermore, stimulate one or more distinct antiinflammatory responses.
Myocardin Suppresses Lipid Uptake in Human VSMC
To corroborate previous in vitro data, further studies were performed to test the functional relevance of reduced VSMC inflammatory activation in the presence of increased myocardin expression. We previously noted that myocardin expression causes downregulation of the scavenger receptor Olr-1 ( Figure 3D ). OLR-1 mediates oxidized low-density lipoprotein (oxLDL) uptake in VSMCs, contributing to foam cell formation and progression of vascular disease. 45 To examine whether OLR-1 downregulation translated functionally to reduced lipid uptake, HCASMC were incubated with fluorescent dil-labeled oxLDL. A marked, significant reduction in dil-oxLDL uptake in Ad.Myocd-treated VSMCs was measured at both 2 and 3 hours after addition, versus controls (P<0.01; Figure 4 ). Myocardin-induced OLR-1 downregulation in VSMC is, thereby consistent with a functional reduction in pathological cellular lipid uptake.
Myocardin Expression in VSMC Suppresses Macrophage Chemotaxis, Adhesion, and Lipid Uptake In Vitro
Activated VSMCs are known to contribute to the recruitment and maturation of circulating leukocytes, and subsequent propagation of lesion inflammation, through the secretion of a diverse assortment of chemokines, including CCL2, CSF-1, IL-6, and CX3CL1. 7, 46, 47 We reasoned that myocardin expression in VSMCs would attenuate the leukocyte chemotactic response through downregulation of many such factors. To test this, a transwell migration assay model was adopted, wherein cultured VSMC were assessed for their ability to induce migration of fluorescently labeled macrophages through a transwell insert membrane ( Figure XIII in the online-only Data Supplement). Prestimulation of control rat VSMCs with IL-1β produced a marked induction of macrophage chemotaxis across the transwell insert membrane, and this migration was significantly attenuated by myocardin expression in the VSMCs (P<0.05; Figure 5A ). In a separate experiment, adhesion of macrophages after incubation with a rat VSMC monolayer was similarly quantified. Lesiondwelling macrophages are known to interact with resident VSMCs, providing synergistic enhancement of proinflammatory responses, such as IL-6 and CCL2 production. 48 Again, macrophage adherence was increased when VSMCs were pretreated with IL-1β, but this increase was strongly abrogated in VSMCs that had been previously administered with Ad.Myocd (P<0.01; Figure 5B ). This is consistent with our observation that myocardin expression reduces the abundance of VSMC surface adhesion molecules, such as CX3CL1 and VCAM. Another critical interaction in early atherogenesis is the tethering of circulating monocytes to activated endothelial cells (ECs) at the vessel wall. 49 Although ECs do not themselves express myocardin, ECs and underlying VSMCs conceivably participate in extensive inflammatory cross-talk. Thus, reduced VSMC inflammatory activation could translate to reduced EC stimulation and reduced EC-leukocyte tethering. Accordingly, conditioned media were collected from pretreated rat VSMCs, and used to prestimulate EC monolayers. Macrophage adhesion to the monolayers was then quantified as previously ( Figure XIIB in the online-only Data Supplement). Results demonstrated a small but significant increase in macrophage tethering to ECs treated with conditioned media from IL-1β-stimulated VSMCs. This increase was not seen in ECs treated with conditioned media from Ad.Myocd-treated VSMCs (P<0.05; Figure 5C ). In a final in vitro functional assay, conditioned media from pretreated rat VSMCs was tested for its ability to influence lipid uptake in macrophages, which represents another central process in atherosclerotic lesion progression. 4 Macrophages were maintained in the conditioned media and then assayed for uptake of fluorescent Dil-labeled acetylated-LDL. Lipid uptake was significantly increased after exposure to conditioned media from IL-1β-treated VSMCs, but this increase was completely abrogated when the VSMCs had been treated with Ad.Myocd (Figure 5D and 5E). To validate the relevance of these findings across species boundaries, macrophage chemotaxis and interaction assays were further repeated with HCASMC in place of rat VSMC, and the same myocardin-mediated suppression of both processes was consistently observed ( Figure XIVA and XIVB in the online-only Data Supplement). Therefore, myocardin-induced repression of VSMC inflammatory activation may functionally regulate several key processes in atherogenesis, including EC-leukocyte tethering, leukocyte chemotaxis, VSMC-leukocyte interaction, and macrophage lipid uptake.
Myocardin Overexpression Reduces Neointimal Response and Macrophage Accumulation In Vivo
Transluminal wire injury is an established procedure to induce endothelial denudation and vascular injury response in mouse carotid arteries. Performing transluminal wire injury in atherosclerosis-prone ApoE −/− , hypercholesterolemic mice 50 is further known to induce the formation of a neointima that shares numerous characteristic features with developing atherosclerotic lesions, including significant macrophage infiltration and even the appearance of cholesterol crystals. This model was, therefore, adopted as a means to study the functional effects of increased myocardin expression in VSMCs, during a vascular disease-like situation, in vivo. Wire injury of left common carotids was performed and Ad.LacZ control or Ad.Myocd adenoviruses were applied intraluminally. Efficient transduction and elevated expression of Myocd and SMC marker genes after Ad.Myocd administration is documented in our recent report 25 because to reduce animal usage, both the studies used sections from the same mice. Ad.LacZ permeation and subsequent β-galactosidase expression throughout the vessel media was demonstrated and is reproduced here in Figure IB in the online-only Data Supplement. We hypothesized here that administration of Ad.Myocd would reduce macrophage accumulation at the site of carotid injury. Formation of a LAMP2-positive macrophage-rich neointima was evident in both the groups, but seemed attenuated in arteries administered with Ad.Myocd. Manual quantification of LAMP2-positive cells in each section confirmed that application of Ad.Myocd to VSMCs at the site of injury had significantly suppressed macrophage accumulation at the site of vascular injury by 2-fold (P<0.05; Figure 6A and 6B). This result is consistent with the previous in vitro data. These studies, therefore, provide strong in vivo evidence to support the conclusion that increased expression of myocardin in VSMC is functionally protective against the onset of inflammatory vascular disease.
Discussion
Atherosclerosis is a multifactorial, chronic inflammatory disease of the vasculature. The development of this condition involves a complex interplay between cells resident in the vascular wall, and infiltrating cells of the innate and adaptive immune system. Contractile, quiescent VSMCs can undergo phenotypic transitions and become proliferative, migratory, and secrete extracellular matrix. VSMCs may additionally undergo a process of inflammatory activation, wherein cells release a diverse range of chemokines and cytokines, take up oxidized lipids, and interact with infiltrating immune cells to help propagate inflammation and disease. An expanding body of literature continues to report correlative associations between pathological VSMC phenotypic modulation, vascular injury or vascular disease progression, and reduced expression of myocardin. [17] [18] [19] [20] [21] However, no study to date has addressed the question of whether reduced myocardin expression in VSMC is necessary or indeed a potentiating factor in the progression of these clinically important phenomena.
We recently identified myocardin as a critical regulator of the arterial response to wire injury. 25 We now show for the first time that myocardin is a central negative regulator of VSMC inflammatory activation and pathological vascular disease. Myocardin haploinsufficiency promoted accelerated inflammation and atherosclerosis in hypercholesterolemic mice, compared with myocardin-normal controls. VSMCs cultured from myocardin-heterozygous-null mice retained a phenotype of reduced myocardin levels and increased inflammatory activation potential compared with WT controls. Furthermore, knockdown of myocardin expression reproduced the effect of increased inflammatory activation potential in cultured HCASMCs. Conversely, raised expression of myocardin in VSMCs potently but specifically suppressed the induction of an array of inflammatory cytokines, chemokines, and adhesion molecules, while upregulating one or more anti-inflammatory mediators. Functionally, expression of myocardin in VSMCs reduced oxidized lipid uptake, leukocyte chemotaxis, leukocyte-VSMC interaction, leukocyte-endothelial tethering and leukocyte lipid uptake in vitro, and attenuated macrophage accumulation within a developing murine lesion in vivo.
Myocardin-null mice die during early development, 13 and thus cannot be used as a loss-of-function model in atherosclerosis. However, myocardin-heterozygous-null mice are viable, and we recently reported a phenotype of reduced aortic myocardin expression, and augmented neointima formation in response to injury with increased SMC migration and proliferation. 25 Our finding that myocardin-heterozygousnull mice exhibit accelerated atherogenesis is consistent with the hypothesis that myocardin depletion is a causal factor in the pathological VSMC phenotypic transition. Together these studies present a compelling demonstration that endogenous levels of myocardin represent a critical regulator of both the vessel injury response and vascular disease. This is corroborated by the in vitro observation that VSMCs cultured from myocardin-heterozygous-null aortas retained reduced myocardin levels and an increased propensity for inflammatory activation, compared with myocardin WT controls. Similarly, increased inflammatory activation in HCASMCs after siRNA-mediated depletion of myocardin further supports these findings and the relevance of myocardin in regulating VSMC inflammatory activation and vascular disease in humans.
Myocardin potently and specifically reduced the production of a diverse range of proinflammatory cytokines, chemokines, and adhesion molecules by cultured VSMCs in response to IL-1β stimulation. Myocardin strongly inhibited the expression of the intracellular proinflammatory pathway mediators CEBPB and CEBPD, which are known to synergistically upregulate and sustain inflammatory gene expression after SMC stimulation. [36] [37] [38] Importantly, suppression of these mediators was able to reverse the increased inflammatory activation in myocardin-deficient VSMCs partially, suggesting that suppression of CEBP factors is a mechanism through which myocardin regulates inflammatory gene expression. That this reversal was only partial, however, implies the existence of additional levels of myocardinmediated inflammatory regulation, possibly involving the upregulation of anti-inflammatory mediators IL-19, SOCS-2, and SOCS-6, which provide interesting avenues for future research. [40] [41] [42] Of interesting note, the specific CSF-3 found in our study to be upregulated by myocardin in VSMC has been recently linked to decreased plaque area, lipid accumulation, and macrophage infiltration into atherosclerotic lesions of ApoE −/− mice. 51 A caveat of these experiments is the difficulty of adequately reducing a complex process, such as atherosclerosis to a basic in vitro model. Much current research analyses cellular responses to a single stimulus in culture, whereas cells in vivo are exposed to multiple stimuli simultaneously and elicit integrated responses accordingly. Cross-talk between individual stimuli can significantly affect the SMC inflammatory phenotype. 7 Compounding these complexities are species differences, and the fact that cells dispersed from organs rarely behave as in vivo. In an effort to address some of these issues, this study demonstrates reproducible suppression of a diverse array of VSMC inflammatory responses by myocardin, after IL-1β stimulation and presents consistent results using cells isolated from rat, mouse, and human sources.
Basic models of VSMC/macrophage and VSMC/EC/macrophage cellular interaction were used to simulate events that occur in a developing lesion, and to assess how increased myocardin expression in VSMCs might influence such interactions. Myocardin expression in VSMCs was shown to suppress oxidized lipid uptake, macrophage chemotaxis, endothelial tethering, VSMC-macrophage interaction, and macrophage lipid uptake in vitro. Testing of these effects in vivo was performed using a mouse model of lesion-inducing vascular injury. 50 Indeed, adenoviral-mediated expression of myocardin in VSMCs significantly reduced macrophage accumulation in developing lesions. Together, these data provide compelling evidence that myocardin is a central regulator of vascular disease, and furthermore, that strategies to prevent or reverse the loss of myocardin expression in VSMCs illustrated in schematic Figure 6C , could protect against inflammation, disease onset, and progression.
On the strength of presented and previous evidence, 25 we propose myocardin as a guardian of the quiescent, differentiated, contractile, and noninflammatory VSMC phenotype, with loss of myocardin representing a critical permissive step in allowing the process of VSMC phenotypic modulation and inflammatory activation to occur at the onset of vascular disease. Methods to maintain or increase myocardin expression may protect aortic and coronary artery VSMCs from entering dysfunctional programs of synthetic and inflammatory activation. Seventy percentage of clinical events in patients with coronary artery disease still cannot be prevented with modern drug therapy, including statins, emphasizing an urgent need for supplementary treatment strategies. 52 Ultimately, myocardin may represent an attractive therapeutic target with multiple antiproliferative, antimigratory and potent, specific anti-inflammatory properties. A future challenge may be to target such therapies specifically to aortic and coronary VSMCs because studies report deleterious effects of increased myocardin expression in cerebral VSMCs 53 and cardiomyocytes. 54 However, successfully tailored myocardin-activating therapies could overcome problems of individual inflammatory pathway redundancy, yet maintain a high degree of VSMC-specificity, thereby reducing off-target, undesirable side effects on the immune system as a whole. Further research into the nature of VSMC inflammation and the specific mechanisms, by which myocardin regulates this process will aid in this endeavour, and await exploration. J.M. Miano provided critical analysis; S. Sinha supervised the project and all authors edited the article. We thank N. Figg for processing and sectioning the blood vessels and J. Harrison, L. Baker, and Dr Laure Gambardella for skilled technical assistance. We thank Prof. Gary Owens for the adenovirus vectors-LacZ, FLAG-tagged myocardin and myocardin dominant negative and Prof E. Olson for the myocardin heterozygous-null mice.
